Európai Unió - olasz - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - diminuzione della pressione intraoculare elevata nei pazienti adulti con ipertensione oculare o glaucoma ad angolo aperto (vedere la sezione 5. riduzione della pressione intraoculare elevata in pazienti pediatrici di età compresa tra 3 anni < 18 anni con ipertensione oculare o glaucoma pediatrico.

Európai Unió - olasz - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleato - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - oslif breezhaler è indicato per il trattamento broncodilatatore di mantenimento dell'ostruzione del flusso aereo in pazienti adulti con malattia polmonare ostruttiva cronica.

Európai Unió - olasz - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - imaging dei radionuclidi - radiofarmaci diagnostici - questo medicinale è solo per uso diagnostico. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Európai Unió - olasz - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatica neoplasie, castrazione-resistente - radiofarmaci terapeutici - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - diclofenac - diclofenac

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

immedica pharma ab - betaxololo - betaxololo

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - valsartan - valsartan

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - micofenolato mofetile - micofenolato mofetile

Európai Unió - olasz - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - agenti antineoplastici - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

novartis consumer health s.p.a. - glicerolo - glicerolo